Detalhe da pesquisa
1.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Eur J Haematol
; 111(5): 715-721, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37501508
2.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
BMC Cancer
; 22(1): 147, 2022 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123422
3.
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Haematologica
; 104(4): 797-804, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30467205
4.
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Haematologica
; 103(12): 2079-2087, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237264
5.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Haematologica
; 101(12): 1573-1580, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27198718
6.
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Br J Haematol
; 164(5): 684-93, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24313224
7.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Haematologica
; 104(5): e208-e210, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514799
8.
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Cancers (Basel)
; 16(5)2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473382
9.
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.
Cancer Rep (Hoboken)
; 5(11): e1614, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243814
10.
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
J Hematol Oncol
; 13(1): 115, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32819447
11.
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Cancer Chemother Pharmacol
; 81(1): 183-193, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29177954
12.
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Cancer Med
; 7(6): 2256-2268, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29673108